Wyeth loratadine deal
This article was originally published in The Tan Sheet
Impax Labs to supply Wyeth Consumer Healthcare with generic OTC forms of Schering-Plough's Claritin-D 12-hour, 24-hour extended release tablets, Hayward, Calif.-based firm reports June 20. "Semi-exclusive" worldwide agreement allows Impax to license products to companies other than Wyeth, demands up-front milestone payments. Deal appears to cover loratadine forms other than those sought in Wyeth's 505(b)(2) application submitted to FDA early this year (1"The Tan Sheet" Feb. 4, 2002, p. 3)...
You may also be interested in...
Schering-Plough's lawsuits against McNeil Consumer Healthcare and Whitehall-Robins could at least temporarily relieve FDA of having to make a highly charged public policy decision on whether to advocate a forced switch of second-generation antihistamines
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.